Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2015

MECHANICSBURG, Pa., Oct. 29, 2015 /PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical") (NYSE: SEM) today announced results for its third quarter ended September 30, 2015.

For the third quarter ended September 30, 2015, net operating revenues increased 34.7% to $1,021.1 million, compared to $758.1 million for the same quarter, prior year.  Income from operations was $48.2 million for the third quarter ended September 30, 2015, compared to $66.0 million for the same quarter, prior year.  Income before income taxes included a non-operating, one-time gain of $29.6 million on the sale of an equity investment in the third quarter ended September 30, 2015. Net income attributable to Select Medical was $29.4 million for the third quarter ended September 30, 2015, compared to $26.5 million for the same quarter, prior year.  Net income before interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, Concentra acquisition costs, equity in earnings (losses) of unconsolidated subsidiaries, and gain on sale of equity investment ("Adjusted EBITDA") for the third quarter ended September 30, 2015 decreased to $84.5 million, compared to $86.8 million for the same quarter, prior year.  A reconciliation of net income to Adjusted EBITDA is presented in table VIII of this release. Income per common share for the third quarter ended September 30, 2015 was $0.22 on a fully diluted basis compared to income per common share of $0.20 for the same quarter, prior year. 

For the nine months ended September 30, 2015, net operating revenues increased 17.9% to $2,703.5 million compared to $2,293.4 million for the same period, prior year.  Income from operations was $212.5 million for the nine months ended September 30, 2015, compared to $226.7 million for the same period, prior year. Income before income taxes included a non-operating, one-time gain of $29.6 million on the sale of an equity investment in the nine months ended September 30, 2015. Net income attributable to Select Medical was $101.4 million for the nine months ended September 30, 2015, compared to $94.9 million for the same period, prior year.  Net income attributable to Select Medical for the nine months ended September 30, 2014 includes a loss on early retirement of debt, net of tax, of $1.4 million.  Adjusted EBITDA for the nine months ended September 30, 2015 increased 4.7% to $298.3 million compared to $285.0 million for the same period, prior year.  A reconciliation of net income to Adjusted EBITDA is presented in table VIII of this release.  Income per common share for the nine months ended September 30, 2015 was $0.77 on a fully diluted basis compared to income per common share of $0.71 for the nine months ended September 30, 2014.  Excluding the loss related to the early retirement of debt and the related tax effect, adjusted income per common share was $0.72 per diluted share for the nine months ended September 30, 2014.  A reconciliation of net income per common share to adjusted income per common share for the nine months ended September 30, 2014 is presented in table IX of this release. 

Specialty Hospital Segment

For the third quarter ended September 30, 2015, net operating revenues for the specialty hospital segment increased 1.1% to $562.3 million, compared to $556.3 million for the same quarter, prior year.  Adjusted EBITDA for the specialty hospital segment decreased to $53.7 million for the third quarter ended September 30, 2015, compared to $81.0 million for the same quarter, prior year.  The Adjusted EBITDA margin for the segment was 9.5% for the third quarter ended September 30, 2015, compared to 14.6% for the same quarter, prior year.  The Adjusted EBITDA results for the specialty hospital segment include start-up losses of approximately $3.1 million for the third quarter ended September 30, 2015 and $3.9 million for the same quarter, prior year.  Certain specialty hospital key statistics for both the third quarter ended September 30, 2015 and 2014 are presented in table VI of this release.

For the nine months ended September 30, 2015, net operating revenues for the specialty hospital segment increased 4.4% to $1,753.4 million, compared to $1,678.8 million for the same period, prior year.  Adjusted EBITDA for the specialty hospital segment for the nine months ended September 30, 2015 decreased to $241.6 million, compared to $261.8 million for the same period, prior year.  The Adjusted EBITDA margin for the segment was 13.8% for the nine months ended September 30, 2015, compared to 15.6% for the same period, prior year.  The Adjusted EBITDA results for the specialty hospital segment include start-up losses of approximately $11.9 million for the nine months ended September 30, 2015 and $8.6 million for the same period, prior year.  Certain specialty hospital key statistics for both the nine months ended September 30, 2015 and 2014 are presented in table VII of this release.

Outpatient Rehabilitation Segment

For the third quarter ended September 30, 2015, net operating revenues for the outpatient rehabilitation segment decreased to $199.6 million, compared to $201.7 million for the same quarter, prior year.  Adjusted EBITDA for the outpatient rehabilitation segment increased 3.5% to $23.8 million for the third quarter ended September 30, 2015, compared to $23.0 million for the same quarter, prior year.  The Adjusted EBITDA margin for the segment was 11.9% for the third quarter ended September 30, 2015, compared to 11.4% for the same quarter, prior year.  Certain outpatient rehabilitation key statistics for both the third quarter ended September 30, 2015 and 2014 are presented in table VI of this release.

For the nine months ended September 30, 2015, net operating revenues for the outpatient rehabilitation segment decreased to $603.8 million, compared to $614.4 million for the same period, prior year.  Adjusted EBITDA for the outpatient rehabilitation segment for the nine months ended September 30, 2015 increased 0.3% to $74.7 million, compared to $74.4 million for the same period, prior year.  The Adjusted EBITDA margin for the segment was 12.4% for the nine months ended September 30, 2015, compared to 12.1% for the same period, prior year.  Certain outpatient rehabilitation key statistics for both the nine months ended September 30, 2015 and 2014 are presented in table VII of this release. 

Concentra Segment

On June 1, 2015, MJ Acquisition Corporation, a joint venture that Select Medical created with Welsh, Carson, Anderson & Stowe XII, L.P. ("WCAS"), consummated the acquisition of Concentra Inc. ("Concentra"), which provides occupational health, consumer health, physical therapy, and veteran's healthcare services throughout the United States. Select Medical owns 50.1% of the voting interests of Concentra Group Holdings, LLC, the indirect parent of Concentra. Concentra's financial results are consolidated with Select Medical's effective June 1, 2015.

For the third quarter ended September 30, 2015, net operating revenues for the Concentra segment were $259.0 million.  Adjusted EBITDA for the Concentra segment was $25.6 million for the third quarter ended September 30, 2015.  The Adjusted EBITDA margin for the Concentra segment was 9.9% for the third quarter ended September 30, 2015.  Certain Concentra key statistics for the third quarter ended September 30, 2015 are presented in table VI of this release.

For the period beginning June 1, 2015 through September 30, 2015, net operating revenues for the Concentra segment were $345.8 million.  Adjusted EBITDA for the Concentra segment was $36.8 million for the period ended September 30, 2015.  The Adjusted EBITDA margin for the Concentra segment was 10.6% for the period ended September 30, 2015.  Certain Concentra key statistics for the period ended September 30, 2015 are presented in table VII of this release.

Stock Repurchase Program

The board of directors of Select Medical has authorized a $500.0 million stock repurchase program that will remain in effect until December 31, 2016, unless extended or earlier terminated by the board of directors.  Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Select Medical deems appropriate.  Select Medical is funding this program with cash on hand and borrowings under Select's revolving facility. During the three and nine months ended September 30, 2015, Holdings repurchased 1,032,334 shares at a cost of approximately $13.6 million, an average cost per share of $13.20, which includes transaction costs. Since the inception of the program through September 30, 2015, Holdings has repurchased 35,924,128 shares at a cost of approximately $314.7 million, or $8.76 per share, which includes transaction costs.

Business Outlook

Select Medical is updating its most recent business outlook after reporting third quarter 2015 financial performance. We now expect for the full year of 2015 consolidated net operating revenues to be in the range of $3.675 billion to $3.725 billion, Adjusted EBITDA in the range of $400.0 million to $410.0 million and fully diluted income per common share for the full year 2015 to be in the range of $0.92 to $0.97.

The Concentra segment is expected to contribute approximately $575.0 million of net operating revenues, approximately $55.0 million of Adjusted EBITDA and approximately $0.01 fully diluted income per common share, which amounts are included in the above revised business outlook.

Select Medical's business outlook includes expected Adjusted EBITDA start-up losses during the full year 2015 of approximately $17.0 million at Select Medical's long term acute care hospitals and inpatient rehabilitation facilities recently opened or under development.

Conference Call

Select Medical will host a conference call regarding its third quarter results and its business outlook on Friday, October 30, 2015, at 9:00am EDT. The domestic dial in number for the call is 1-877-474-9506. The international dial in number is 1-857-244-7559. The passcode for the call is 13517703. The conference call will be webcast simultaneously and can be accessed at Select Medical's website www.selectmedicalholdings.com.

For those unable to participate in the conference call, a replay will be available until 11:59pm EST, November 6, 2015. The replay number is 1-888-286-8010 (domestic) or 1-617-801-6888 (international). The passcode for the replay will be 47193544. The replay can also be accessed at Select Medical's website, www.selectmedicalholdings.com.

Select Medical began operations in 1997 and has grown to be one of the largest operators of specialty hospitals and outpatient rehabilitation clinics in the United States based on number of facilities.  On June 1, 2015, a joint venture created by Select Medical and WCAS consummated the acquisition of Concentra, which provides occupational health, consumer health, physical therapy, and veteran's healthcare services throughout the United States.  As of September 30, 2015, Select Medical operated 110 long term acute care hospitals and 17 acute medical rehabilitation hospitals in 28 states, and 1,033 outpatient rehabilitation clinics in 31 states and the District of Columbia.  Select Medical's contract therapy business provides medical rehabilitation services on a contracted basis to nursing homes, hospitals, assisted living and senior care centers, schools, and work sites.  Concentra operated 300 centers in 38 states.  Concentra also provides contract services at employer worksites and Department of Veterans Affairs community-based outpatient clinics.  Select Medical had operations in 46 states and the District of Columbia. Information about Select Medical is available at www.selectmedical.com.

Certain statements contained herein that are not descriptions of historical facts are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995).  Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:

• changes in government reimbursement for our services due to the implementation of healthcare reform legislation, deficit reduction measures, and/or new payment policies (including, for example, the expiration of the moratorium limiting the full application of the 25 Percent Rule that would reduce our Medicare payments for those patients admitted to a long term acute care hospital from a referring hospital in excess of an applicable percentage admissions threshold) may result in a reduction in net operating revenues, an increase in costs and a reduction in profitability;

• the impact of the Bipartisan Budget Act of 2013, which establishes new payment limits for Medicare patients who do not meet specified criteria, may result in a reduction in net operating revenues and profitability of our long term acute care hospitals;

• the failure of our specialty hospitals to maintain their Medicare certifications may cause our net operating revenues and profitability to decline;

• the failure of our facilities operated as "hospitals within hospitals" to qualify as hospitals separate from their host hospitals may cause our net operating revenues and profitability to decline;

• a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;

• acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources or expose us to unforeseen liabilities;

• our plans and expectations related to the Concentra acquisition, including expectations regarding the expected capital expenditures related to the acquisition, and our ability to realize anticipated synergies;

• private third-party payors for our services may undertake future cost containment initiatives that could limit our future net operating revenues and profitability;

• the failure to maintain established relationships with the physicians in the areas we serve could reduce our net operating revenues and profitability;

• shortages in qualified nurses, therapists, physicians, or other licensed providers could increase our operating costs significantly or limit our ability to staff our facilities;

• competition may limit our ability to grow and result in a decrease in our net operating revenues and profitability;

• the loss of key members of our management team could significantly disrupt our operations;

• the effect of claims asserted against us could subject us to substantial uninsured liabilities; and

• other factors discussed from time to time in our filings with the Securities and Exchange Commission, including factors discussed under the heading "Risk Factors" of our quarterly report on Form 10-Q and of the annual report on Form 10-K.

Investor inquiries:
Joel T. Veit
Senior Vice President and Treasurer
717-972-1100
[email protected] 

 

VIII.  Net Income to Adjusted EBITDA Reconciliation
For the Three and Nine Months Ended September 30, 2014 and 2015
(In thousands, unaudited)

The following table reconciles net income to Adjusted EBITDA for Select Medical.  Adjusted EBITDA is used by Select Medical to report its segment performance.  Adjusted EBITDA is defined as net income before interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, Concentra acquisition costs, equity in earnings (losses) of unconsolidated subsidiaries, and gain on sale of equity investment. The Company believes that the presentation of Adjusted EBITDA is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry.  Adjusted EBITDA is used by management to evaluate financial performance and determine resource allocation for each of its operating units.

Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles.  Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance.  Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity.  Because Adjusted EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies. 

SOURCE Select Medical Holdings Corporation